Clinical Trials Using ATR Kinase Inhibitor AZD6738

Clinical trials are research studies that involve people. The clinical trials on this list are studying ATR Kinase Inhibitor AZD6738. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-11 of 11
  • Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

    This phase II trial studies how well olaparib and ceralasertib (AZD6738) work in treating patients with IDH mutant cholangiocarcinoma or solid tumors. Cancer is caused by changes (mutations) to genes that control the way cells function. Laboratory studies have shown that olaparib and AZD6738 can shrink IDH mutant tumors or stop them from growing. Olaparib and ceralasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 9 locations

  • Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1 / PD-L1 Containing Therapy

    This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1 / PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.
    Location: 6 locations

  • AZD6738 for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Standard Therapy

    This phase Ib trial studies the side effects, best dose, and response to AZD6738 in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia progressing on standard therapy. DNA is the genetic material that serves as the body’s instruction book. Cancer is caused by changes (mutations) to genes (DNA) that control the way cells function. AZD6738 blocks a protein called ATR. ATR notices when there is injury to DNA and works to repair that damage. Studies done in a laboratory setting and cell lines suggest that myelodysplastic syndrome and chronic myelomonocytic leukemia cells rely specifically on the ATR pathway (a network of genes that interact with ATR) to fix DNA damage and survive; by inhibiting ATR with AZD6738, myelodysplastic syndrome or chronic myelomonocytic leukemia cells appear to selectively accumulate DNA damage and die, but healthy cells appear to be less sensitive to this drug. Inhibiting ATR may be a way to selectively target myelodysplastic syndrome or chronic myelomonocytic leukemia cells for treatment.
    Location: 5 locations

  • Ascending Doses of Ceralasertib in Combination With Chemotherapy and / or Novel Anti Cancer Agents

    This is a modular, phase I / phase 1 b, open-label, multicentre study of ceralasertib administered orally in combination with cytotoxic chemotherapy regimens and / or novel anti-cancer agents, to patients with advanced malignancies. The study design allows an investigation of optimal combination dose of ceralasertib with other anti-cancer treatments, with intensive safety monitoring to ensure the safety of the patients. The initial combination to be investigated is ceralasertib with carboplatin. The second combination to be investigated is ceralasertib with Olaparib. The third combination to be investigated is ceralasertib with durvalumab.
    Location: 6 locations

  • A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

    To investigate the effectiveness and tolerability of a second maintenance treatment in participants with platinum-sensitivity relapsed (PSR) epithelial ovarian cancer, who have previously received PARPi maintenance treatment and who have benefit (complete response [CR] or partial response [PR]) or stable disease (SD) from further platinum based chemotherapy.
    Location: 7 locations

  • Olaparib and Ceralasertib for the Treatment of Patients with Recurrent or Refractory Osteosarcoma with or without Suspected Lung Metastases

    This phase II trial studies the effect of olaparib and ceralasertib in treating patients with osteosarcoma that has come back (recurrent) or has not responded to treatment (refractory) that may or may not have spread to the lungs (suspected lung metastases). Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Ceralasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving olaparib and ceralasertib may work better than standard treatment, including chemotherapy and / or radiation therapy, in treating patients with osteosarcoma.
    Location: 2 locations

  • Olaparib and Ceralasertib in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    This phase II trial studies how well olaparib and ceralasertib work in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). Olaparib and ceralasertib work by blocking proteins important for repairing damage to deoxyribonucleic acid (DNA). When this damage cannot be repaired, tumor cells die. This trial is being done to test the effectiveness of olaparib and ceralasertib in treating patients with metastatic castration-resistant prostate cancer.
    Location: 3 locations

  • AZD6738 and Olaparib in Treating Patients with Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    This phase II trial studies how well AZD6738 and olaparib work in treating patients with high grade ovarian, primary peritoneal, or fallopian tube cancer that has come back. AZD6738 and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Olaparib with Cediranib or Ceralasertib for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

    This phase II trial studies how well olaparib with cediranib or ceralasertib works in treating patients with germline BRCA mutated breast cancer that has spread to other places in the body (advanced or metastatic). Olaparib, cediranib, and ceralasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Ceralasertib with or without Olaparib in Treating Patients with Locally Advanced or Metastatic Solid Tumors

    This phase II trial studies how well ceralasertib works alone or in combination with olaparib in treating patients with solid tumors that have spread to nearby tissue or lymph nodes or other parts of the body. Ceralasertib and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not known if giving ceralasertib with or without olaparib may work better in treating patients with solid tumors.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

    This biomarker study has been designed to assess the effects of different agents in both tumour tissue and peripheral samples to help inform the best combinations of DDR agents with immuno-oncology (IO) therapies. In the first instance 2 DDR agents will be assessed separately as monotherapy. Additional arms may be added later to evaluate other DDR agents and / or DDR and immunotherapy agents in combination or in sequence. The primary objective of the study is to investigate immune activation due to DDR inhibition by assessing tumour and blood samples of patients treated with study investigational agent(s).
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania